Published in Clin Cancer Res on March 01, 2006
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res (2009) 1.79
The role of Src in solid tumors. Oncologist (2009) 1.72
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther (2010) 1.67
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res (2009) 1.54
Nonreceptor tyrosine kinases in prostate cancer. Neoplasia (2007) 1.50
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Regulation of SRC family kinases in human cancers. J Signal Transduct (2011) 1.32
Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci U S A (2013) 1.32
miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene (2013) 1.24
The dual kinase complex FAK-Src as a promising therapeutic target in cancer. Onco Targets Ther (2010) 1.22
Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res (2010) 1.20
Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res (2008) 1.16
Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res (2009) 1.13
The C-kit receptor-mediated signal transduction and tumor-related diseases. Int J Biol Sci (2013) 1.13
Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis. Mol Carcinog (2010) 1.12
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function. J Cancer Sci Ther (2009) 1.11
Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat (2010) 1.10
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells. Neoplasia (2007) 1.07
Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett (2010) 1.06
Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One (2012) 1.06
Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer (2011) 1.06
Potential molecular mechanism for c-Src kinase-mediated regulation of intestinal cell migration. J Biol Chem (2008) 1.01
alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling. Mol Cancer Ther (2008) 0.97
Migfilin interacts with Src and contributes to cell-matrix adhesion-mediated survival signaling. J Biol Chem (2009) 0.95
Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res (2011) 0.93
Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res (2011) 0.93
A Phosphotyrosine Proteomic Screen Identifies Multiple Tyrosine Kinase Signaling Pathways Aberrantly Activated in Malignant Mesothelioma. Genes Cancer (2010) 0.93
Increases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo. Neoplasia (2006) 0.92
Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. Mol Cancer (2009) 0.92
Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells. BMC Cancer (2013) 0.92
Role of c-Src activity in the regulation of gastric cancer cell migration. Oncol Rep (2014) 0.91
Reversion-induced LIM interaction with Src reveals a novel Src inactivation cycle. J Cell Biol (2009) 0.90
Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop. Oncogene (2012) 0.90
Liver-specific expressions of HBx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish. PLoS One (2013) 0.87
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem (2012) 0.87
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis. Oncotarget (2015) 0.86
Control of mammary tumor differentiation by SKI-606 (bosutinib). Oncogene (2010) 0.86
Contribution of bone tissue modulus to breast cancer metastasis to bone. Cancer Microenviron (2011) 0.85
Autophagic action of new targeting agents in head and neck oncology. Cancer Biol Ther (2012) 0.85
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res (2009) 0.82
The role of Src family kinases in growth and migration of glioma stem cells. Int J Oncol (2014) 0.81
Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer. PLoS One (2015) 0.81
Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors: answers and unsolved problems. Int J Mol Sci (2012) 0.81
Dasatinib synergizes with JSI-124 to inhibit growth and migration and induce apoptosis of malignant human glioma cells. J Carcinog (2010) 0.80
The role of SRC family kinases in prostate cancer. Transl Oncogenomics (2007) 0.80
Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck (2013) 0.80
Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. Gastrointest Cancer Res (2007) 0.79
Integrating biologically targeted therapy in head and neck squamous cell carcinomas. Semin Radiat Oncol (2009) 0.78
A Polymorphic Variant of AFAP-110 Enhances cSrc Activity. Transl Oncol (2010) 0.78
Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo. Mol Ther Nucleic Acids (2012) 0.77
Src transformation of colonic epithelial cells: enhanced anchorage-independent growth in an Apc(+/min) background. Mol Carcinog (2009) 0.77
Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src. Oncotarget (2016) 0.77
Fibroblast growth factor-2 autofeedback regulation in pituitary folliculostellate TtT/GF cells. Endocrinology (2009) 0.77
Src family kinases differentially influence glioma growth and motility. Mol Oncol (2015) 0.77
Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer. PLoS One (2013) 0.76
Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget (2015) 0.76
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab? Ther Adv Med Oncol (2013) 0.75
Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours. Br J Cancer (2014) 0.75
Cytotoxicity of the Sesquiterpene Lactones Neoambrosin and Damsin from Ambrosia maritima Against Multidrug-Resistant Cancer Cells. Front Pharmacol (2015) 0.75
Molecular imaging metrics to evaluate response to preclinical therapeutic regimens. Front Biosci (Landmark Ed) (2011) 0.75
Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells. Exp Ther Med (2017) 0.75
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res (2017) 0.75
Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. Oncotarget (2017) 0.75
Src SUMOylation Inhibits Tumor Growth Via Decreasing FAK Y925 Phosphorylation. Neoplasia (2017) 0.75
Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev (2003) 4.62
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res (2009) 4.19
Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol (2007) 4.12
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res (2009) 3.57
Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc (2009) 3.36
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene (2005) 2.53
ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One (2011) 2.49
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol (2006) 2.07
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer (2002) 2.03
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell (2007) 1.97
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res (2002) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res (2005) 1.83
Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res (2003) 1.80
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol (2003) 1.75
Src activation regulates anoikis in human colon tumor cell lines. Oncogene (2002) 1.70
The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat (2004) 1.69
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57
Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol (2005) 1.55
Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem (2007) 1.54
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res (2005) 1.54
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res (2009) 1.54
Src continues aging: current and future clinical directions. Clin Cancer Res (2007) 1.50
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer (2011) 1.49
Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res (2003) 1.41
Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther (2006) 1.39
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res (2006) 1.38
Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer (2011) 1.34
Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res (2005) 1.34
SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem (2007) 1.32
Involvement of the conserved adaptor protein Alix in actin cytoskeleton assembly. J Biol Chem (2006) 1.30
AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest (2007) 1.30
Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis (2006) 1.26
The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs (2011) 1.24
BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res (2011) 1.23
Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol (2011) 1.23
GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One (2009) 1.20
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res (2003) 1.17
AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells. J Cell Physiol (2007) 1.17
Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res (2007) 1.14
c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas (2005) 1.14
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther (2005) 1.13
Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol (2010) 1.12
Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res (2008) 1.10
Src, chemoresistance and epithelial to mesenchymal transition: are they related? Anticancer Drugs (2007) 1.10
The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model. Oncogene (2005) 1.08
Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res (2011) 1.08
Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis (2003) 1.07
Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res (2005) 1.06
Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg (2005) 1.06
Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis (2006) 1.03
Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Targets (2007) 1.03
Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther (2008) 1.02
Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. Mol Cancer Res (2013) 1.01
Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Mol Ther (2005) 1.01
Decoding the intrinsic mechanism that prohibits ALIX interaction with ESCRT and viral proteins. Biochem J (2010) 0.98
A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am J Pathol (2003) 0.97
SRC inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem (2006) 0.96
Targeting SRC in mucinous ovarian carcinoma. Clin Cancer Res (2011) 0.93
Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer (2013) 0.92
Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. J Exp Ther Oncol (2007) 0.91
Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res (2003) 0.91
Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol (2007) 0.88
Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways. PLoS One (2012) 0.88
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs (2012) 0.87
Src signaling pathways in prostate cancer. Cancer Metastasis Rev (2014) 0.86
A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res (2012) 0.86
Extracellular Alix regulates integrin-mediated cell adhesions and extracellular matrix assembly. EMBO J (2008) 0.86
Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression. Cancer Res (2006) 0.85
Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clin Cancer Res (2004) 0.85
Targeting SRC and tubulin in mucinous ovarian carcinoma. Clin Cancer Res (2013) 0.83
Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation. Proc Natl Acad Sci U S A (2010) 0.83
Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. Int J Oncol (2006) 0.81
Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck (2013) 0.80
AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro Oncol (2010) 0.80
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer. Prostate (2013) 0.78
Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog (2010) 0.78
Proteomics profiling of exosomes from primary mouse osteoblasts under proliferation versus mineralization conditions and characterization of their uptake into prostate cancer cells. J Proteome Res (2017) 0.75